Ubs Group Ag Atai Life Sciences N.V. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Ubs Group Ag holds 26,386 shares of ATAI stock, worth $35,621. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,386

Previous 27,328 3.45%

Holding current value

$35,621

Previous $36,000 16.67%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.16 - $1.64 $1,092 - $1,544	-942 Reduced 3.45%	26,386 $30,000
Q2 2024 Aug 13, 2024	BUY	$1.27 - $2.6 $3,111 - $6,370	2,450 Added 9.85%	27,328 $36,000
Q1 2024 May 13, 2024	SELL	$1.5 - $2.19 $9,007 - $13,150	-6,005 Reduced 19.44%	24,878 $49,000
Q4 2023 Feb 09, 2024	BUY	$1.04 - $1.55 $1,277 - $1,903	1,228 Added 4.14%	30,883 $43,000
Q2 2023 Aug 11, 2023	SELL	$1.44 - $2.19 $144 - $219	-100 Reduced 0.34%	29,655 $51,000
Q1 2023 May 12, 2023	SELL	$1.17 - $2.7 $3,699 - $8,537	-3,162 Reduced 9.61%	29,755 $53,000
Q4 2022 Feb 08, 2023	BUY	$2.38 - $3.55 $8,239 - $12,290	3,462 Added 11.75%	32,917 $87,000
Q3 2022 Nov 10, 2022	SELL	$3.14 - $4.87 $1,142 - $1,772	-364 Reduced 1.22%	29,455 $98,000
Q2 2022 Aug 10, 2022	BUY	$3.03 - $5.32 $32,181 - $56,503	10,621 Added 55.32%	29,819 $109,000
Q1 2022 May 16, 2022	SELL	$4.66 - $7.66 $2,469 - $4,059	-530 Reduced 2.69%	19,198 $98,000
Q4 2021 Feb 14, 2022	BUY	$6.82 - $17.8 $132,498 - $345,818	19,428 Added 6476.0%	19,728 $150,000
Q3 2021 Nov 15, 2021	BUY	$13.62 - $19.48 $2,724 - $3,896	200 Added 200.0%	300 $4,000
Q2 2021 Aug 13, 2021	BUY	$16.94 - $19.89 $1,694 - $1,989	100 New	100 $2,000

Others Institutions Holding ATAI

# of Institutions

Shares Held

12.4M

Call Options Held

77.8K

Put Options Held

50.3K

View Full List

About ATAI Life Sciences N.V.

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $224M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

More about ATAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account